N,N-dimethyl-1-[5-[3-[7-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-imidazo[4,5-c]pyridin-2-yl]-2H-indazol-5-yl]pyridin-3-yl]methanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N,N-dimethyl-1-[5-[3-[7-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-imidazo[4,5-c]pyridin-2-yl]-2H-indazol-5-yl]pyridin-3-yl]methanamine
• 化学式: C₂₆H₃₁N₉
• 分子量: 469.6
• InChiKey: DYJJZBKGFLECOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  88.2
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF
  申请人：Samumed, LLC

  公开号：US20140179696A1

  公开（公告）日：2014-06-26

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明揭示了用于治疗各种疾病和病理的吲唑化合物。更具体地说，本发明涉及使用吲唑化合物或其类似物，治疗其特征为Wnt通路信号激活的障碍（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺病和骨关节炎），调节由Wnt通路信号介导的细胞事件，以及由于Wnt通路和/或一个或多个Wnt信号组分的突变或失调而引起的遗传疾病和神经系统情况/障碍/疾病。还提供了治疗Wnt相关疾病状态的方法。
• US8987298B2
  申请人：——

  公开号：US8987298B2

  公开（公告）日：2015-03-24